H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 5 and set a price target of $45.00. The company's shares closed last Tuesday at $6.00, close to its 52-week low of $5.70. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -11.3% and a 25.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.94.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-actinium-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Actinium Pharmaceuticals Charts.